Case Western Reserve University researchers have found early evidence that semaglutide can temper nicotine cravings.
Semaglutide doesn't work for everyone and can have side effects, but a study in mice may point to a solution.
New research suggests GLP-1 drugs like Ozempic can help prevent up to 10 different obesity-related cancers in people with type 2 diabetes.
Roughly 42% of Americans are obese, making the U.S. a huge market for anti-obesity drugs.
More than a third of former semaglutide regained their shed pounds, however.
This week's biggest science stories include a future Moon base and a Stone Age cemetery.
People with alcohol use disorder who took semaglutide, also known as Wegovy, drank less and had fewer cravings for alcohol, new research found.
The active ingredient in Mounjaro, tirzepatide, is expected to soon be the next major obesity treatment but is already being sold through sketchy sources.
The FDA has received adverse event reports from people using compounded semaglutide, which might not contain the same version of the popular obesity drug.
People given oral semaglutide lost about 15% of their weight over 68 weeks, according to the company.
Celebrities and other influencers on social media, including Elon Musk, have posted about using the drug.
The American Academy of Pediatrics' guidelines are the first to emphasize proactive measures for treating childhood obesity, which has risen in recent years.
The next generation of obesity treatments, a controversial Alzheimer's drug, and male birth control are all coming in 2023.
As of 2021, 19 states and territories have at least 35% of their residents living with obesity—more than double the number in 2018.
Novo Nordisk, the company behind new obesity drug Wegovy, reported that the demand for the drug is higher than what it can currently supply.
Doctors and potential patients are hopeful about Wegovy, but is it really the miracle it's hyped up to be, and will it contribute to medical fatphobia?
Mode
Follow us
